AUPH vs AZN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AUPH and AZN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AUPH and AZN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company whose flagship product is LUPKYNIS (voclosporin), approved by the FDA in January 2021 as the first oral therapy for adult patients with active lupus nephritis, a form of kidney inflammation caused by lupus. That approval gave Aurinia a differentiated position: LUPKYNIS is the only approved oral treatment specifically for the condition, and it is also approved in Japan and marketed in Europe with partners. Unlike most small biotechs, Aurinia has turned this single product into a genuinely profitable, cash-generative business, reporting revenue growth in the 20% to 34% range in recent years, LUPKYNIS net product sales that continued climbing, positive net income, meaningful operating cash flow, and a substantial cash and investments balance.

Full AUPH guide

AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.

Full AZN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AUPH drivers: LUPKYNIS growth and exclusivity; Profitability and cash returns.
• AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is single-product concentration: with revenue and profits driven overwhelmingly by LUPKYNIS, any setback in sales, reimbursement, safety, or exclusivity would hit the whole business, since there is no diversified portfolio to cushion it. For AZN, the dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time.

Pick AUPH if you believe its drivers more; AZN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AUPH and AZN guides.

AUPH. These figures are qualitative and tied to the asOf date; verify live revenue, earnings, cash, and per-share numbers with Aurinia's latest filings before acting. Some headline net-income figures have been boosted by one-time items such as deferred-tax adjustments, so operating results give a cleaner read than the bottom line alone. Because so much of the value hinges on how long LUPKYNIS holds exclusivity, any valuation is really a judgment on patent durability, sales growth, and whether the pipeline or a buyout adds value.

AZN. Figures are approximate and tied to the asOf date; confirm live numbers before acting. AstraZeneca trades as a growth-oriented large-cap pharma, so its valuation reflects confidence in the pipeline delivering on the $80 billion 2030 goal more than any single current metric. A patent cliff early next decade means today's revenue base is not guaranteed to persist, so how you weigh future launches matters more than trailing multiples.

Headline figures (approximate, Jul 2026): AUPH shows business model Commercial-stage biopharma concentrated on one product, LUPKYNIS (voclosporin) for lupus nephritis, revenue trend Growing, with recent year-over-year growth roughly in the 20% to 34% range, driven by LUPKYNIS net product sales, profitability Profitable with positive operating cash flow, unusual for a small-cap biotech; some reported net income figures reflect one-time tax items, so read carefully, balance sheet Substantial cash and investments; has funded share repurchases and an acquisition; AZN shows revenue (ttm) Around $60 billion; 2025 total revenue was about $58.7 billion, up roughly 9%, with Q1 2026 up about 8% at constant currency, growth drivers Oncology (Tagrisso, Imfinzi, Calquence, Enhertu, Lynparza), rare disease (Ultomiris, Soliris) and metabolic launches; company ambition of $80 billion revenue by 2030, margins/profitability Solidly profitable large-cap pharma; heavy, sustained R&D spending funds the pipeline that the 2030 target depends on, dividend Pays a regular dividend; recent yield roughly 2%, modest for the sector but backed by large, growing cash flows.

AUPH and AZN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AUPH and AZN exposure against your real portfolio. It is not an investment adviser.